REG - AstraZeneca PLC - AstraZeneca prices a EUR1.5bn bond offering

AstraZenecaAnnouncement

24/02/2023 18:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230224:nRSX0503Ra&default-theme=true

RNS Number : 0503R  AstraZeneca PLC  24 February 2023

24 February 2023 18:15 GMT

 

 

AstraZeneca prices €1.5 billion bond offering

 

AstraZeneca PLC ("AstraZeneca") announces that, on 24 February 2023, it
successfully priced €750 million of fixed rate notes with a coupon of 3.625%
maturing on 3 March 2027 and €750 million of fixed rate notes with a coupon
of 3.750% maturing on 3 March 2032 (the "Notes").

 

AstraZeneca expects to use the net proceeds of the offering for general
corporate purposes, including refinancing of existing indebtedness.

 

The Notes will be issued under the US$10,000,000,000 EMTN programme of
AstraZeneca and AstraZeneca Finance LLC and admitted to listing on the UK
Financial Conduct Authority's Official List and to trading on the London Stock
Exchange's Main Market.

 

The Notes have not been registered under the U.S. Securities Act of 1933 and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration.

 

This announcement shall not constitute an offer to sell or the solicitation of
an offer to buy the Notes described herein, nor shall there be any sale of
these Notes in any jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the securities
laws of any such jurisdiction.

 

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Twitter @AstraZeneca (http://www.twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IODPPUUPPUPWGMC